Kenneth R. Durbin

Kenneth R. Durbin

Auto-generated profile, based on publicly available information

Kenneth R. Durbin

Proteinaceous, Inc

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2022 in Science Advances
Verified
Journal Article
Open access
PSPei Su
Pei Su
JMJohn P. McGee
John P. McGee
KDKenneth R. Durbin
Kenneth R. Durbin
MHMichael A. R. Hollas
Michael A. R. Hollas
MYManxi Yang
Manxi Yang
NKNeil Kelleher
Neil Kelleher
Imaging of proteoforms in human tissues is hindered by low molecular specificity and limited proteome coverage. Here, we introduce proteoform imaging mass spectrometry (PiMS), which increases the size limit for proteoform detection and identification by fourfold compared to reported methods and reveals tissue localization of proteoforms at <80-μm spatial resolution. PiMS advances proteoform imaging by combining ambient nanospray desorption electrospray ionization with ion detection using individual ion mass spectrometry. We demonstrate highly multiplexed proteoform imaging of human kidney, annotating 169 of 400 proteoforms of <70 kDa using top-down MS and a database lookup of ~1000 kidney candidate proteoforms, including dozens of key enzymes in primary metabolism. PiMS images reveal distinct spatial localizations of proteoforms to both anatomical structures and cellular neighborhoods in the vasculature, medulla, and cortex regions of the human kidney. The benefits of PiMS are poised to increase proteome coverage for label-free protein imaging of tissues.

12 July 2023 in Journal of Proteome Research
Verified
Journal Article
Open access
KDKenneth R. Durbin
Kenneth R. Durbin
MRMatthew T. Robey
Matthew T. Robey
LVLilien N. Voong
Lilien N. Voong
RFRyan T. Fellers
Ryan T. Fellers
CLCorinne A. Lutomski
Corinne A. Lutomski
NKNeil Kelleher
Neil Kelleher
Native mass spectrometry has recently moved alongside traditional structural biology techniques in its ability to provide clear insights into the composition of protein complexes. However, to date, limited software tools are available for the comprehensive analysis of native mass spectrometry data on protein complexes, particularly for experiments aimed at elucidating the composition of an intact protein complex. Here, we introduce ProSight Native as a start-to-finish informatics platform for analyzing native protein and protein complex data. Combining mass determination via spectral deconvolution with a top-down database search and stoichiometry calculations, ProSight Native can determine the complete composition of protein complexes. To demonstrate its features, we used ProSight Native to successfully determine the composition of the homotetrameric membrane complex Aquaporin Z. We also revisited previously published spectra and were able to decipher the composition of a heterodimer complex bound with two noncovalently associated ligands. In addition to determining complex composition, we developed new tools in the software for validating native mass spectrometry fragment ions and mapping top-down fragmentation data onto three-dimensional protein structures. Taken together, ProSight Native will reduce the informatics burden on the growing field of native mass spectrometry, enabling the technology to further its reach.

29 September 2023 in Journal of Proteome Research
Verified
Journal Article
Open access
JKJake T. Kline
Jake T. Kline
MBMichael W. Belford
Michael W. Belford
CBCornelia L. Boeser
Cornelia L. Boeser
RHRomain Huguet
Romain Huguet
RFRyan T. Fellers
Ryan T. Fellers
LFLuca Fornelli
Luca Fornelli
Blood serum and plasma are arguably the most commonly analyzed clinical samples, with dozens of proteins serving as validated biomarkers for various human diseases. Top-down proteomics may provide additional insights into disease etiopathogenesis since this approach focuses on protein forms, or proteoforms, originally circulating in blood, potentially providing access to information about relevant post-translational modifications, truncations, single amino acid substitutions, and many other sources of protein variation. However, the vast majority of proteomic studies on serum and plasma are carried out using peptide-centric, bottom-up approaches that cannot recapitulate the original proteoform content of samples. Clinical laboratories have been slow to adopt top-down analysis, also due to higher sample handling requirements. In this study, we describe a straightforward protocol for intact proteoform sample preparation based on the depletion of albumin and immunoglobulins, followed by simplified protein fractionation via polyacrylamide gel electrophoresis. After molecular weight-based fractionation, we supplemented the traditional liquid chromatography-tandem mass spectrometry (LC-MS2) data acquisition with high-field asymmetric waveform ion mobility spectrometry (FAIMS) to further simplify serum proteoform mixtures. This LC-FAIMS-MS2 method led to the identification of over 1000 serum proteoforms < 30 kDa, outperforming traditional LC-MS2 data acquisition and more than doubling the number of proteoforms identified in previous studies.

4 October 2024 in Science Advances
Verified
Journal Article
Open access
AJAndrew S. Judd
Andrew S. Judd
BBBhupinder Bawa
Bhupinder Bawa
WBWayne R. Buck
Wayne R. Buck
ZTZhi-Fu Tao
Zhi-Fu Tao
YLYingchun Li
Yingchun Li
ASAndrew Souers
Andrew Souers
Overexpression of the antiapoptotic protein B-cell lymphoma-extra large (BCL-X L ) is associated with drug resistance and disease progression in numerous cancers. The compelling nature of this protein as a therapeutic target prompted efforts to develop selective small-molecule BCL-X L inhibitors. Although efficacious in preclinical models, we report herein that selective BCL-X L inhibitors cause severe mechanism-based cardiovascular toxicity in higher preclinical species. To overcome this liability, antibody-drug conjugates were constructed using altered BCL-X L –targeting warheads, unique linker technologies, and therapeutic antibodies. The epidermal growth factor receptor–targeting antibody-drug conjugate AM1-15 inhibited growth of tumor xenografts and did not cause cardiovascular toxicity nor dose-limiting thrombocytopenia in monkeys. While an unprecedented BCL-X L –mediated toxicity was uncovered in monkey kidneys upon repeat dosing of AM1-15, this toxicity was mitigated via further drug-linker modification to afford AM1-AAA (AM1-25). The AAA drug-linker has since been incorporated into mirzotamab clezutoclax, the first selective BCL-X L –targeting agent to enter human clinical trials.

14 February 2024 in Analytical Chemistry
Verified
Journal Article
Closed access
CHChe-Fan Huang
Che-Fan Huang
JKJake T. Kline
Jake T. Kline
FNFernanda Negrão
Fernanda Negrão
MRMatthew T. Robey
Matthew T. Robey
TTTimothy K. Toby
Timothy K. Toby
LFLuca Fornelli
Luca Fornelli

15 November 2022 in Journal of the American Society for Mass Spectrometry
Verified
Journal Article
Closed access
FPFan Pu
Fan Pu
KKKevan T. Knizner
Kevan T. Knizner
MRMatthew T. Robey
Matthew T. Robey
ARAndrew J. Radosevich
Andrew J. Radosevich
SUScott A. Ugrin
Scott A. Ugrin
JWJon D. Williams
Jon D. Williams